Fda.gov hosts this regulatory reference for dermal fillers inside its Medical Devices section, under aesthetic and cosmetic devices. It treats fillers as what they legally are in the United States: injectable implants, classified as medical devices and subject to approval before they can be marketed. That framing sets the tone for everything underneath. The U.S. Food and Drug Administration: Fillers resource is not a buyer's guide or a clinic finder, and it does not pretend to be. It is a definition of the category, a map of what has been cleared and for whom, and a blunt list of what has not.
Absorbable fillers versus permanent fillers
The definitional groundwork is broad on purpose. The page gathers the terms people actually use, including soft tissue fillers, lip and facial fillers, and wrinkle fillers, and folds them into one regulatory bucket. From there it splits the field into absorbable and non-absorbable products, which is the distinction with the clearest clinical consequence and the one most marketing tends to blur. Absorbable, or temporary, fillers are covered for moderate to severe facial wrinkles, nasolabial folds, and perioral lines, along with augmentation of the lips, cheeks, chin, and the back of the hand. Non-absorbable, or permanent, fillers carry a much narrower remit: nasolabial folds and acne scars on the cheek, and little else. I find that contrast useful precisely because it is stated without softening, since a permanent implant is a different decision than one the body breaks down over months.
Medical uses beyond cosmetic enhancement
Two further approved uses get their own mention, and they anchor the page in medicine rather than vanity. One is correction of facial fat loss, or lipoatrophy, in people with HIV. The other is correction of contour deficiencies such as wrinkles and acne scars. Across all of these, the page repeats a single threshold that is easy to skim past and important to catch: approval is limited to adults aged 22 and older. That age line is the sort of specific the U.S. Food and Drug Administration: Fillers page states because it can, and because it has regulatory weight behind it.
Unapproved sites and contraindicated injection locations
What gives this resource its spine is the section on unapproved and contraindicated uses, which is unusually direct for any page touching cosmetic procedures. It names body sites and procedures that fillers are not approved for and should not be used in: breast augmentation, buttock enlargement, and increasing fullness of the feet. It goes further into anatomy, flagging injection into bone, tendon, ligament, or muscle. And it singles out specific regions of the face and head where injection is called out as contraindicated, including the glabella, the nose, the area around the eyes, the forehead, and the neck.
Serious complications from off-label use
That is a meaningful list, because several of those off-label sites are exactly where complications have a track record of turning serious. A page that only described approved uses would leave a reader with half the picture. By spelling out the boundary, the U.S. Food and Drug Administration: Fillers entry arms a patient with the questions worth asking a practitioner before anything is injected. It also quietly tells you what to be wary of if a provider proposes one of the named off-label sites as routine.
Risk assessment for approved procedures
Alongside the warnings sits a dedicated treatment of the risks of dermal fillers as a general category. The page keeps that separate from the contraindications, which is the correct call. Risk applies even to fully approved, on-label use, and a reader deserves to see it addressed on its own terms rather than buried under the list of what to avoid.
Separate guidance for patients and providers
The page is also built for more than one audience, and it does that without watering down either side. There is patient and consumer information written for someone with no clinical background, and there is separate guidance aimed at health care providers. Those are genuinely different reading needs, and keeping them in distinct sections means a nervous first-timer and a treating physician can both land somewhere useful. Industry stakeholders are served by the same structure.
Checking product approval against federal records
One of the more practical features is the companion sub-page that lists FDA-approved dermal fillers by name. This is the part with real day-to-day value, because it lets someone check a specific product against the federal record instead of taking a clinic's word for its standing. The U.S. Food and Drug Administration: Fillers page points to it as a distinct reference, which keeps the main page readable while leaving the granular product detail one click away for anyone who needs it. A patient can match what a provider proposes to use against an authoritative list, and that is a concrete safeguard, not a vague reassurance.
Context around the page is handled sensibly. It sits within a wider Aesthetic Cosmetic Devices section that links out to neighboring topics, including non-invasive body contouring technologies and microneedling devices. Someone researching fillers is often weighing those adjacent options, so the cross-links serve a real research path. A Spanish-language version is available as well, which widens reach for a procedure category that is far from limited to English speakers.
If there is a limit to what the U.S. Food and Drug Administration: Fillers page can do for an individual, it is the same limit any regulatory reference has: it tells you what is approved and what the rules are, not which clinic near you does good work or what a practitioner will charge. That is by design, and holding it against the page would be a misread of its job. What the U.S. Food and Drug Administration: Fillers resource offers is the authoritative baseline, the version of the facts that a marketing site has every incentive to shade. For a decision involving an implant in your face, that baseline is the thing worth starting from.
It is worth saying plainly how the parts fit. The U.S. Food and Drug Administration: Fillers resource defines the category, separates temporary from permanent products, lists approved uses with their age limit, names the uses to avoid and the body sites to keep needles out of, addresses risk on its own terms, splits its guidance by audience, and connects to a named-product list and related device topics. Each section of the U.S. Food and Drug Administration: Fillers page answers a question a real patient or provider would bring to it.
Compared with the flood of clinic pages and product promotions a search on this topic surfaces, the U.S. Food and Drug Administration: Fillers entry occupies the position none of those can: the source they are all, in theory, regulated against. Reading the rules before the sales pitch is logical, and the U.S. Food and Drug Administration: Fillers page lays those rules out in language a layperson can follow without dumbing them down for the clinician.
That dual reach is harder to pull off than it looks, and the page manages it. The candor about contraindicated sites is the kind of thing a commercial page will rarely volunteer. The U.S. Food and Drug Administration: Fillers material is the federal record on what these implants are cleared to do, produced by the body that does the clearing, so the information has a basis no brochure can replicate.
